SignatureFD’s DiaMedica Therapeutics DMAC Stock Holding History

SignatureFD’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25	Closed	-$108	–	3218
2023 Q2	$108	Buy	+25	New	+$61	﹤0.01%	3175

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return

SignatureFD's DMAC Position: Q3 2023 in Review

SignatureFD sold out of DiaMedica Therapeutics (DMAC) in Q3 2023, closing a stake of 25 shares — an estimated $108 sold.

SignatureFD first reported a position in DMAC in Q2 2023 and held it in 1 quarter. The position peaked at $108 in Q2 2023. 36 funds tracked by Wall St. Rank hold DMAC as of Q3 2023.

SignatureFD reported no remaining DiaMedica Therapeutics position as of Q3 2023 after selling out during the quarter.
SignatureFD sold 25 DiaMedica Therapeutics shares in Q3 2023, an estimated $108.
SignatureFD first reported a position in DiaMedica Therapeutics in Q2 2023 and held it in 1 quarter.
SignatureFD's DiaMedica Therapeutics position peaked at $108 in Q2 2023.
36 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2023.

Based on SignatureFD's 13F filing for Q3 2023, filed 3 Nov 2023.